Allogene Therapeutics (ALLO) Net Cash Flow (2019 - 2025)
Historic Net Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$14.5 million.
- Allogene Therapeutics' Net Cash Flow rose 8784.46% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 2545.12%. This contributed to the annual value of -$7.9 million for FY2024, which is 13734.88% down from last year.
- Latest data reveals that Allogene Therapeutics reported Net Cash Flow of -$14.5 million as of Q3 2025, which was up 8784.46% from $9.9 million recorded in Q2 2025.
- Allogene Therapeutics' Net Cash Flow's 5-year high stood at $119.6 million during Q2 2024, with a 5-year trough of -$119.4 million in Q3 2024.
- In the last 5 years, Allogene Therapeutics' Net Cash Flow had a median value of -$13.4 million in 2021 and averaged -$7.6 million.
- Data for Allogene Therapeutics' Net Cash Flow shows a peak YoY increase of 28888.7% (in 2023) and a maximum YoY decrease of 29435.53% (in 2023) over the last 5 years.
- Over the past 5 years, Allogene Therapeutics' Net Cash Flow (Quarter) stood at -$15.9 million in 2021, then increased by 21.5% to -$12.5 million in 2022, then skyrocketed by 211.69% to $13.9 million in 2023, then skyrocketed by 72.4% to $24.0 million in 2024, then plummeted by 160.54% to -$14.5 million in 2025.
- Its last three reported values are -$14.5 million in Q3 2025, $9.9 million for Q2 2025, and -$32.8 million during Q1 2025.